BioNxt Advances Eurasian Market Strategy with New LOI

BioNxt Solutions Inc. has signed a non-binding letter of intent (LOI) with a focus on commercializing its sublingual cladribine oral thin film (ODF) in Eurasian Patent Organization member states. This move follows recent patent approvals in the Eurasian region and Europe, bolstering BioNxt’s intellectual property portfolio.

The LOI, representing a pathway to a potential licensing deal, involves an exclusive 60-day negotiation period. It includes discussions around licensing rights, financial terms such as upfront payments and royalties, and strategic collaboration in regulatory processes and commercialization.

With patent protection established until 2043 across Eurasia and anticipated coverage in up to 39 European states, BioNxt aims to leverage its technology for market expansion. Targeted at neurological conditions like Multiple Sclerosis, the sublingual delivery system offers a user-friendly alternative to traditional tablets.